Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19

Erin K McCreary(University of Pittsburgh Medical Center), Kevin E. Kip(UPMC Health System), Anna Nakayama, Graham M. Snyder(University of Pittsburgh), Oscar C. Marroquin(University of Pittsburgh), Scott Berry(Queen's University), Amy Crawford(Berry & Associates (United States)), Russell Meyers(University of Pittsburgh), Christopher Seymour(University of Pittsburgh), Michelle Adam(University of Pittsburgh), David T. Huang(University of Pittsburgh), Paula L. Kip(University of Pittsburgh Medical Center), Tami Minnier(University of Pittsburgh Medical Center), Judith A. Shovel(University of Pittsburgh Medical Center), William Garrard(UPMC Health System), J Ryan Bariola(University of Pittsburgh), Debbie Albin(UPMC Health System), Anna McGlothlin(Berry & Associates (United States)), Mary Kay Wisniewski(University of Pittsburgh Medical Center), Mark Schmidhofer(University of Pittsburgh), Lindsay R. Berry(Berry & Associates (United States)), Stephanie K. Montgomery(University of Pittsburgh), Kelsey Linstrum(University of Pittsburgh), Donald M. Yealy(University of Pittsburgh), Derek C. Angus(University of Pittsburgh), Kevin Collins(UPMC Health System), Richard J. Wadas(University of Pittsburgh)
medRxiv
December 1, 2021
Cited by 6


Related Papers